Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotechnology Joins Russell Microcap® Index
08:30am, Thursday, 01'st Jul 2021
FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's prop
NetScientific gives further backing to PDS Biotechnology
04:21am, Tuesday, 22'nd Jun 2021
NetScientific PLC (LON:NSCI) said its portfolio company, PDS Biotechnology Corporation (NASDAQ:PDSB), has closed its underwritten public offering of shares. The shares were offered at US$8.50 a pop.
PDSB Stock Price Increases Over 15%: Why It Happened
03:17pm, Friday, 18'th Jun 2021
The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by over 15% during intraday trading. This is why it happened.
FLORHAM PARK, N.J., June 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing a pipeline
NetScientific: City broker provides thumbs up following PDS funding round
08:49am, Wednesday, 16'th Jun 2021
WH Ireland applauded the progress of NetScientific PLC (LON:NSCI) investee company PDS Biotechnology Corporation (NASDAQ: PDSB), which has unveiled plans to raise US$45mln. The broker said the latest
NetScientific follows its money as investee company announces plans to raise US$45mln
02:22am, Wednesday, 16'th Jun 2021
NetScientific PLC (LON:NSCI) said it is participating in the latest funding round by investee company PDS Biotechnology Corporation (NASDAQ:PDSB). It said it is buying shares worth US$510,000 and is f
PDS Biotech Announces Proposed Offering of Common Stock
04:02pm, Monday, 14'th Jun 2021
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel can
Why PDSB Shares Are Trading Higher Today
10:05am, Tuesday, 08'th Jun 2021
PDS Biotechnology Corp (NASDAQ:PDSB) shares are trading higher by 13.3% at $10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical
NetScientific on the rise again after PDS cancer trial
09:34am, Tuesday, 08'th Jun 2021
NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the Ame
NetScientific PLC on the rise aagain after PDS cancer trial
09:32am, Tuesday, 08'th Jun 2021
NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the Ame
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory ad
PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients
07:44am, Tuesday, 08'th Jun 2021
PDS Biotechnology Corporation (NASDAQ: PDSB) has announced interim data from the Phase 2 trial led by the National Cancer Institute (NCI) evaluating PDS0101 (Versamune-HPV16) in combination with tw
Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory ad
PDS Biotech Shines At The ASCO 2021 Annual Meeting
10:28pm, Thursday, 03'rd Jun 2021
PDSB has gained over 125% since clinical data in an ASCO abstract on its lead cancer therapeutic was published. The company still has lots of room for growth if its lead therapeutic candidate is event
FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacc
